Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections

Christopher H. Goss, Yukihiro Kaneko, Lisa Khuu, Gail D. Anderson, Sumedha Ravishankar, Moira L. Aitken, Noah Lechtzin, Guolin Zhou, Daniel M. Czyz, Kathryn McLean, Oyebode Olakanmi, Howard A. Shuman, Mary Teresi, Ellen Wilhelm, Ellen Caldwell, Stephen J. Salipante, Douglas B. Hornick, Richard J. Siehnel, Lev Becker, Bradley E BritiganPradeep K. Singh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The lack of new antibiotics is among the most critical challenges facing medicine. The problem is particularly acute for Gram-negative bacteria. An unconventional antibiotic strategy is to target bacterial nutrition and metabolism. The metal gallium can disrupt bacterial iron metabolism because it substitutes for iron when taken up by bacteria. We investigated the antibiotic activity of gallium ex vivo, in a mouse model of airway infection, and in a phase 1 clinical trial in individuals with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa airway infections. Our results show that micromolar concentrations of gallium inhibited P. aeruginosa growth in sputum samples from patients with CF. Ex vivo experiments indicated that gallium inhibited key iron-dependent bacterial enzymes and increased bacterial sensitivity to oxidants. Furthermore, gallium resistance developed slowly, its activity was synergistic with certain antibiotics, and gallium did not diminish the antibacterial activity of host macrophages. Systemic gallium treatment showed antibiotic activity in murine lung infections. In addition, systemic gallium treatment improved lung function in people with CF and chronic P. aeruginosa lung infection in a preliminary phase 1 clinical trial. These findings raise the possibility that human infections could be treated by targeting iron metabolism or other nutritional vulnerabilities of bacterial pathogens.

Original languageEnglish (US)
Article numbereaat7520
JournalScience translational medicine
Volume10
Issue number460
DOIs
StatePublished - Sep 26 2018

Fingerprint

Gallium
Therapeutic Uses
Iron
Lung
Infection
Anti-Bacterial Agents
Cystic Fibrosis
Pseudomonas aeruginosa
Clinical Trials, Phase I
Sputum
Gram-Negative Bacteria
Oxidants
Metals
Macrophages
Medicine
Bacteria
Enzymes
Therapeutics
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Goss, C. H., Kaneko, Y., Khuu, L., Anderson, G. D., Ravishankar, S., Aitken, M. L., ... Singh, P. K. (2018). Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections. Science translational medicine, 10(460), [eaat7520]. https://doi.org/10.1126/scitranslmed.aat7520

Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections. / Goss, Christopher H.; Kaneko, Yukihiro; Khuu, Lisa; Anderson, Gail D.; Ravishankar, Sumedha; Aitken, Moira L.; Lechtzin, Noah; Zhou, Guolin; Czyz, Daniel M.; McLean, Kathryn; Olakanmi, Oyebode; Shuman, Howard A.; Teresi, Mary; Wilhelm, Ellen; Caldwell, Ellen; Salipante, Stephen J.; Hornick, Douglas B.; Siehnel, Richard J.; Becker, Lev; Britigan, Bradley E; Singh, Pradeep K.

In: Science translational medicine, Vol. 10, No. 460, eaat7520, 26.09.2018.

Research output: Contribution to journalArticle

Goss, CH, Kaneko, Y, Khuu, L, Anderson, GD, Ravishankar, S, Aitken, ML, Lechtzin, N, Zhou, G, Czyz, DM, McLean, K, Olakanmi, O, Shuman, HA, Teresi, M, Wilhelm, E, Caldwell, E, Salipante, SJ, Hornick, DB, Siehnel, RJ, Becker, L, Britigan, BE & Singh, PK 2018, 'Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections', Science translational medicine, vol. 10, no. 460, eaat7520. https://doi.org/10.1126/scitranslmed.aat7520
Goss, Christopher H. ; Kaneko, Yukihiro ; Khuu, Lisa ; Anderson, Gail D. ; Ravishankar, Sumedha ; Aitken, Moira L. ; Lechtzin, Noah ; Zhou, Guolin ; Czyz, Daniel M. ; McLean, Kathryn ; Olakanmi, Oyebode ; Shuman, Howard A. ; Teresi, Mary ; Wilhelm, Ellen ; Caldwell, Ellen ; Salipante, Stephen J. ; Hornick, Douglas B. ; Siehnel, Richard J. ; Becker, Lev ; Britigan, Bradley E ; Singh, Pradeep K. / Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections. In: Science translational medicine. 2018 ; Vol. 10, No. 460.
@article{d8a006bc2032454987c012142e7fcdc7,
title = "Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections",
abstract = "The lack of new antibiotics is among the most critical challenges facing medicine. The problem is particularly acute for Gram-negative bacteria. An unconventional antibiotic strategy is to target bacterial nutrition and metabolism. The metal gallium can disrupt bacterial iron metabolism because it substitutes for iron when taken up by bacteria. We investigated the antibiotic activity of gallium ex vivo, in a mouse model of airway infection, and in a phase 1 clinical trial in individuals with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa airway infections. Our results show that micromolar concentrations of gallium inhibited P. aeruginosa growth in sputum samples from patients with CF. Ex vivo experiments indicated that gallium inhibited key iron-dependent bacterial enzymes and increased bacterial sensitivity to oxidants. Furthermore, gallium resistance developed slowly, its activity was synergistic with certain antibiotics, and gallium did not diminish the antibacterial activity of host macrophages. Systemic gallium treatment showed antibiotic activity in murine lung infections. In addition, systemic gallium treatment improved lung function in people with CF and chronic P. aeruginosa lung infection in a preliminary phase 1 clinical trial. These findings raise the possibility that human infections could be treated by targeting iron metabolism or other nutritional vulnerabilities of bacterial pathogens.",
author = "Goss, {Christopher H.} and Yukihiro Kaneko and Lisa Khuu and Anderson, {Gail D.} and Sumedha Ravishankar and Aitken, {Moira L.} and Noah Lechtzin and Guolin Zhou and Czyz, {Daniel M.} and Kathryn McLean and Oyebode Olakanmi and Shuman, {Howard A.} and Mary Teresi and Ellen Wilhelm and Ellen Caldwell and Salipante, {Stephen J.} and Hornick, {Douglas B.} and Siehnel, {Richard J.} and Lev Becker and Britigan, {Bradley E} and Singh, {Pradeep K.}",
year = "2018",
month = "9",
day = "26",
doi = "10.1126/scitranslmed.aat7520",
language = "English (US)",
volume = "10",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "460",

}

TY - JOUR

T1 - Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections

AU - Goss, Christopher H.

AU - Kaneko, Yukihiro

AU - Khuu, Lisa

AU - Anderson, Gail D.

AU - Ravishankar, Sumedha

AU - Aitken, Moira L.

AU - Lechtzin, Noah

AU - Zhou, Guolin

AU - Czyz, Daniel M.

AU - McLean, Kathryn

AU - Olakanmi, Oyebode

AU - Shuman, Howard A.

AU - Teresi, Mary

AU - Wilhelm, Ellen

AU - Caldwell, Ellen

AU - Salipante, Stephen J.

AU - Hornick, Douglas B.

AU - Siehnel, Richard J.

AU - Becker, Lev

AU - Britigan, Bradley E

AU - Singh, Pradeep K.

PY - 2018/9/26

Y1 - 2018/9/26

N2 - The lack of new antibiotics is among the most critical challenges facing medicine. The problem is particularly acute for Gram-negative bacteria. An unconventional antibiotic strategy is to target bacterial nutrition and metabolism. The metal gallium can disrupt bacterial iron metabolism because it substitutes for iron when taken up by bacteria. We investigated the antibiotic activity of gallium ex vivo, in a mouse model of airway infection, and in a phase 1 clinical trial in individuals with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa airway infections. Our results show that micromolar concentrations of gallium inhibited P. aeruginosa growth in sputum samples from patients with CF. Ex vivo experiments indicated that gallium inhibited key iron-dependent bacterial enzymes and increased bacterial sensitivity to oxidants. Furthermore, gallium resistance developed slowly, its activity was synergistic with certain antibiotics, and gallium did not diminish the antibacterial activity of host macrophages. Systemic gallium treatment showed antibiotic activity in murine lung infections. In addition, systemic gallium treatment improved lung function in people with CF and chronic P. aeruginosa lung infection in a preliminary phase 1 clinical trial. These findings raise the possibility that human infections could be treated by targeting iron metabolism or other nutritional vulnerabilities of bacterial pathogens.

AB - The lack of new antibiotics is among the most critical challenges facing medicine. The problem is particularly acute for Gram-negative bacteria. An unconventional antibiotic strategy is to target bacterial nutrition and metabolism. The metal gallium can disrupt bacterial iron metabolism because it substitutes for iron when taken up by bacteria. We investigated the antibiotic activity of gallium ex vivo, in a mouse model of airway infection, and in a phase 1 clinical trial in individuals with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa airway infections. Our results show that micromolar concentrations of gallium inhibited P. aeruginosa growth in sputum samples from patients with CF. Ex vivo experiments indicated that gallium inhibited key iron-dependent bacterial enzymes and increased bacterial sensitivity to oxidants. Furthermore, gallium resistance developed slowly, its activity was synergistic with certain antibiotics, and gallium did not diminish the antibacterial activity of host macrophages. Systemic gallium treatment showed antibiotic activity in murine lung infections. In addition, systemic gallium treatment improved lung function in people with CF and chronic P. aeruginosa lung infection in a preliminary phase 1 clinical trial. These findings raise the possibility that human infections could be treated by targeting iron metabolism or other nutritional vulnerabilities of bacterial pathogens.

UR - http://www.scopus.com/inward/record.url?scp=85054057700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054057700&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aat7520

DO - 10.1126/scitranslmed.aat7520

M3 - Article

C2 - 30257953

AN - SCOPUS:85054057700

VL - 10

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 460

M1 - eaat7520

ER -